Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-04-10 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report (审计报告) issued by a certified public accounting firm (大信会计师事务所) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters such as revenue recognition and goodwill impairment, responsibilities of management and auditors, and includes extensive financial statements (consolidated and parent company balance sheets, income statements) and notes for the fiscal year ended December 31, 2019. The content is comprehensive and includes actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The length and detail confirm it is a standalone audit report. FY 2019
2020-04-10 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors expressing their opinions on various company matters including the 2019 profit distribution plan, remuneration of directors and senior management, internal control self-evaluation report, reappointment of the audit firm for 2020, accounting policy changes, and external guarantees and related party fund occupation. It references compliance with laws, regulations, and company articles, and provides detailed independent opinions on these corporate governance and financial matters. The document is not a full annual report or audit report but rather an independent directors' opinion statement on company affairs, which is typically part of governance or board-related disclosures. It is not a short announcement or certification but a substantive opinion document. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level independent director opinions on company matters.
2020-04-10 Chinese
内部控制规则落实自查表
Audit Report / Information Classification · 90% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit committee operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a formal audit report or annual report. It does not contain financial statements or financial performance data. It is also not a brief announcement or a certification letter. The content focuses on internal control compliance and audit committee activities, which aligns with an Audit Report / Information (AR) filing type, as it relates to internal audit and control results but is not a full annual report. The document length is under 5,000 characters, but it is substantive and not merely an announcement. Therefore, the best fit is AR (Audit Report / Information). FY 2019
2020-04-10 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, location, voting procedures, agenda items including the 2019 annual report, profit distribution plan, reappointment of auditors, and amendments to the company charter. It also contains instructions for shareholder registration and proxy voting. The document is not the annual report itself but a formal notification to shareholders about the AGM and the matters to be discussed and voted on. The length (5588 characters) and content confirm it is a meeting notice rather than a report or voting results announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-04-10 Chinese
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fifth board of directors of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It includes approvals of the 2019 annual general manager work report, 2019 board work report, 2019 annual report and its summary, profit distribution plan, internal control self-evaluation report, appointment of the 2020 audit firm, accounting policy changes, credit line application, 2020 Q1 report, equity acquisition, business scope expansion and amendments to the company charter, and the proposal to convene the 2019 annual shareholders meeting. The document contains substantive content such as financial results, profit distribution details, audit firm appointment, and internal control reports. It is not merely an announcement of a report publication but includes actual resolutions and financial data. The document is not a full annual report itself but a board meeting resolution announcement covering multiple reports and proposals, including the annual report and quarterly report. Given the nature of the document as a board meeting resolutions announcement, it fits best under Board/Management Information (MANG).
2020-04-10 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 年第一季度报告正文" which translates to "2020 First Quarter Report". It contains detailed financial data for the first quarter of 2020, including revenue, net profit, cash flow, assets, liabilities, shareholder information, and other financial metrics. The document includes comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly). It is not a brief announcement or a certification but a full quarterly report with substantive financial data and explanations. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.